The SPDR S&P Biotech ETF (XBI) traded as high as $80.89 per share on Monday June 26th, essentially meeting our $81.00 upside target first mentioned in our May 1st Keys To This Week report, to capture a 14% gain in a little less than 2 months.
For perspective, during the same period the S&P 500 rose by just 1%.
Here is the chart from our May 1st report.
Here is the updated version of that chart through the close today.
Asbury Research subscribers can view our current research on the US stock market, market sectors, US interest rates, ETFs and commodities, as well as a table that includes our current and recent stock and ETF picks like XBI, by logging into the Research Center via the big gold button in the upper right corner of the screen.